OUR BLOGS

In recent weeks, an astonishing number of states have taken up the fight against #BigPharma to lower prescription drug prices. In fact, two-thirds of states are currently considering proposals that would make medications more affordable, and many of these states are looking at personal prescription importation from licensed, legitimate online pharmacies in Canada as one possible solution. According to the National Academy for State Health Policy, a whopping 87 bills in 34 sta

This new video – Big Pharma: Market Failure – looks at the impact of outrageous drug prices in the U.S. on the public, businesses and overall economy. This in-depth look at the problem of high priced #pharmaceuticals helps put this into perspective, there is nothing stopping #BigPharma from charging whatever they want for medications regardless of their value. The typical #BigPharma arguments are explored and discredited. As they waive the banner for being champions of resea

Earlier this month, seven senators introduced legislation to slow the revolving door between federal agencies and the pharmaceutical companies that those agencies are charged with regulating. Fast forward to yesterday, President Donald Trump officially nominates Alex Azar – former president of one of the largest #BigPharma companies in the world – to lead the Department of Health and Human Services (HHS), which is responsible for overseeing healthcare and federal public healt

A new study shows that US employers are bracing for an increase in healthcare expenses in 2018 as costs of new #pharmaceuticals to treat cancer, MS, and hepatitis C are expected to rise more than 7 percent, as reported by the New York Times. Approximately 40-50 new specialty drugs are readying to hit the market each year in the next 5 years, which is expected to increase spending on #pharmaceuticals by $25 billion annually. The authors attribute the problem primarily to the i

David Lazarus, in this LA Times story, exposes questionable practices of #BigPharma to appear to care about patients through Patient Assistance Programs that on the surface seem to subsidize the cost of exorbitantly priced #pharmaceuticals. Yet the reality is that these programs often fall flat in helping patients, but can be helpful in arming pharma companies with slick promotions on how they are helping consumers afford their medications. As we have seen time and again from

#BigPharma claims that they need to maintain the high price of #pharmaceuticals in order to fund research and development for future cures and treatments. Don’t believe the hype! New data compares the amount of spending on R&D compared to prescription drug sales among the top ten #BigPharma companies. Here’s the reality: #BigPharma spends a fraction of revenue generated from prescription drug sales on R&D. Check out this chart from the Pharmaceutical Executive: http://read.bi